

LJMU Research Online

Ennis, S, McGregor, G, Hamborg, T, Jones, H, Shave, R, Singh, SJ and Banerjee, P

Randomised feasibility trial into the effects of low-frequency electrical muscle stimulation in advanced heart failure patients.

http://researchonline.ljmu.ac.uk/id/eprint/7326/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Ennis, S, McGregor, G, Hamborg, T, Jones, H, Shave, R, Singh, SJ and Banerjee, P (2017) Randomised feasibility trial into the effects of lowfrequency electrical muscle stimulation in advanced heart failure patients. BMJ Open. 7 (8). ISSN 2044-6055

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/

1 Randomised feasibility trial into the effects of low frequency electrical muscle

2 stimulation in advanced heart failure patients

Stuart Ennis^{1,4}, Gordon McGregor^{1,6}, Thomas Hamborg ², Helen Jones³, Robert
 Shave⁴, Sally J Singh^{5,6} and Prithwish Banerjee^{1,6}.

11 Abstract

- 12 **Objectives:** Low Frequency Electrical Muscle Stimulation (LF-EMS) may have the
- 13 potential to reduce breathlessness and increase exercise capacity in the chronic
- 14 heart failure population who struggle to adhere to conventional exercise. The study's
- aim was to establish if a randomised controlled trial of LF-EMS was feasible.
- 16 **Design and setting:** Double blind (participants, outcome assessors), randomised
 17 study in a secondary care outpatient cardiac rehabilitation program.
- 18 Participants: Severe heart failure patients (New York Heart Association class III-IV) 19 with left ventricular ejection fraction <40% documented by echocardiography were</p>
- 20 eligible.
- 21 Interventions: Participants were randomised(remotely by computer) to 8 weeks (5 x
- 22 60 mins per week) of either LF-EMS intervention (4Hz, continuous, n=30) or SHAM
- 23 placebo (skin level stimulation only, n=30) of the quadriceps and hamstrings
- 24 muscles. Participants used the LF-EMS straps at home and were supervised weekly
- 25 **Outcome measures:** Recruitment, adherence and tolerability to the intervention
- were measured during the trial as well as physiological outcomes (primary outcome:
- 6 minute walk, secondary outcomes: quadriceps strength, quality of life and physical
- activity).
- 29 **Results:** Sixty of 171 eligible participants (35.08%) were recruited to the trial. 12
- 30 (20%) of the 60 patients (4 LF-EMS, 8 SHAM) withdrew. Forty one patients (68.3 %),
- 31 adhered to the protocol for at least 70% of the sessions. The physiological measures
- 32 indicated no significant differences between groups in 6 minute walk
- distance, (P=0.13) and quality of life, (P=0.55) although both outcomes improved
 more with LF-EMS.
- 35 **Conclusion:** Severe heart failure patients can be recruited to and tolerate LF-EMS
- 36 studies. A larger Randomised Controlled Trial (RCT) in the advanced heart failure
- 37 population is technically feasible, although adherence to follow-up would be
- 38 challenging. The preliminary improvements in exercise capacity and quality of life
- 39 were minimal and this should be considered if planning a larger trial.

40 Trial registration number: ISRCTN16749049

41

45

42 Strengths and Limitations

- To our knowledge, this was the first study to evaluate the design of a study into
 LF-EMS in advanced (NYHA III-IV) heart failure patients
 - Analysis of recruitment, retention and adherence in this hard to reach group
- 46 contributes useful knowledge to the heart failure literature on how practical
 47 exercise interventions could be implemented.
- This study was a real-world feasibility study. Advanced heart failure patients
 were recruited when deemed eligible by experienced clinicians based on
 available information. This approach can be subjective and lead to variability in
 disease severity in our sample. However this is in keeping with the pragmatic
 aim of our trial and provides external validity to our findings.
- 53
 4. This study had a small sample size, and was not powered or designed to
 54 assess the effects of LF-EMS in advanced heart failure. The findings should
 55 therefore be considered preliminary.
- 56

57 Introduction

58

Chronic Heart Failure (CHF) affects approximately 26 million people worldwide, ¹
and is associated with a poor prognosis; 30- 40% of patients diagnosed with heart
failure die within a year. ² Patients in New York Heart Association (NYHA) class
III/IV are unable to perform the simplest daily activities, become depressed and have
a poor quality of life.³

64 Regular aerobic exercise reduces breathlessness and muscle dysfunction for 65 individuals with CHF whilst improving exercise capacity.^{4,5,6} According to the 66 ExTraMATCH meta-analysis,⁷ exercise training leads to a 35% relative reduction in 67 mortality, similar to the effects of beta-blockers⁸ and ACE inhibitors.⁹ However, 68 those with advanced CHF are often so limited that they are unable to gain the holistic 69 benefits of exercise.^{4,7}

70 Electrical Muscle Stimulation (EMS) may provide an alternative rehabilitative 71 therapy for this group. In patients with mild to moderate CHF, EMS can improve 72 muscle strength of the legs, exercise capacity and quality of life. ^{10,11,12} Low 73 frequency (4-5Hz) electrical muscle stimulation (LF-EMS) produces shivering-like 74 sub-tetanic muscle contractions that can stimulate an aerobic response equivalent to 51% of maximal oxygen uptake.¹³ Therapeutic levels of aerobic exercise can thus be 75 achieved passively by LF-EMS,¹⁴ and it has been shown to be comfortable and well 76 77 tolerated in healthy individuals and those with mild to moderate CHF. ^{15,16} However, 78 the impact of LF-EMS in advanced heart failure (NYHA class III/IV) patients is 79 currently unknown. As advanced heart failure patients have shown poor uptake and 80 adherence to intervention studies,¹⁷ a preliminary study was needed to determine the 81 feasibility of LF-EMS in this patient cohort prior to the development of a large-scale 82 definitive trial.

83 Based upon recommendations for good practice in the design of pilot and feasibility studies ¹⁸ this study was undertaken with the following aims: To (a) test the 84 robustness of the study protocol for a potential future trial, (b) estimate rates of 85 recruitment, consent and retention, (c) determine the tolerability of the LF-EMS 86 87 intervention and the effectiveness of the sham placebo in the NYHA III/IV CHF population, and (d) gain initial estimates of the efficacy of LF-EMS for all potential 88 89 primary outcomes. This can be used for sample size calculations in future 90 substantive trials.

92 Methods

93 Experimental Design

This feasibility study used a double blind parallel group randomised control design. Participants were randomised to either LF-EMS or 'sham' placebo for a period of eight weeks and blinded to group allocation. Outcomes were assessed at baseline (pre randomisation), eight weeks and 20 weeks follow-up.

98 Recruitment and screening

Between October 2013 and March 2015, University Hospital Coventry and Warwickshire, (UHCW) Hospital NHS Trust heart failure clinics lists were screened for patients fulfilling the eligibility criteria for the study. Sixty eligible participants were recruited. The study conformed to the Declaration of Helsinki and was approved by the local NHS Ethics Committee. All participants provided written informed consent.

104 Randomisation

105 The trial statistician, in conjunction with Warwick Clinical Trials Unit generated 106 the randomisation sequence remotely (by computer) using permuted block 107 randomisation. Group allocation was concealed from outcomes assessors and 108 participants.

109 **Participants**

110 Male and female adults, >18 years old, with stable CHF, documented by echocardiography of left ventricular systolic dysfunction (ejection fraction < 40%) 111 112 were eligible for the study. All participants had New York Heart Association (NYHA) 113 functional class III-IV symptoms as judged by an experienced heart failure cardiologist. Participants were required to be medically stable, defined as the 114 absence of hospital admission or alterations in medical therapy within the preceding 115 116 two weeks. Exclusion criteria for safety and practical reasons were: (1) presence of 117 implantable cardiac devices, (2) serious cardiac arrhythmias,(3) neurological 118 disorders or previous stroke significant enough to limit exercise, (4) orthopaedic 119 problems that prevented walking, (5) neuromuscular disease, (6) dementia or (7) a 120 mid-thigh circumference of more than 50cm (due to the size of the LF-EMS straps).

121 **LF-EMS Stimulation**

122 The LF-EMS equipment (Biomedical Research Limited, Galway, Ireland) 123 consisted of a pair of neoprene straps containing built-in adhesive gel electrodes. 124 The equipment is CE marked under the European Medical Device Directive. The 125 stimulator current waveform was designed to produce rhythmical contractions in the 126 leg muscle groups occurring at a pulse frequency of 4-5Hz (pulse width: 620µs). 127 The maximum peak output pulse current used was 140mA.

128 LF-EMS intervention

129 Participants used the LF-EMS or sham placebo for one hour, five times a 130 week, for eight consecutive weeks. Of the five hourly sessions per week, four were completed unsupervised in the participant's own home. The remaining session was
 conducted in a cardiac rehabilitation outpatient setting under the supervision of an
 exercise physiologist. The LF-EMS technology was retrospectively interrogated (i.e.
 at the weekly supervised sessions) to report date, frequency, duration and
 stimulation intensity.

136 **'Sham' Placebo intervention**

In the sham arm of the study, participants were provided with identical straps
and electrodes. In contrast to the LF-EMS group the controller was programmed to
deliver a very low level of stimulation (Frequency: 99Hz, pulse width: 150µs,
maximum current amplitude: 7.3mA). This provided sensory input to the skin surface
but little or no muscle activation. Participants in the sham group had the same
induction, supervision and follow-up as the intervention arm.

143 Outcome Measures

144 **Feasibility criteria**

In relation to the design of pilot and feasibility studies, Thabane et al,¹⁹
 recommends stipulating criteria for success '*a priori*'. The feasibility criteria were:

147 1. Recruitment rate – At least 40% of eligible participants recruited to the trial

Retention – no more than 33% of participants drop out during the interventionperiod.

151

148

1523.Adherence – 66% of participants tolerate the intervention and adhere to the153protocol for \geq 70% of the intervention period.

154

155 4. *Placebo efficacy-* Participants would be able to guess their group allocation
156 no more often than would be expected by chance.

157

158 **Primary outcome**

159 Six Minute Walk Test (6MWT).

160 The 6MWT was conducted in accordance with the American Thoracic Society 161 (ATS) guidelines.²⁰ Participants were instructed to walk as far as possible in six 162 minutes along a 30m, flat, obstacle free corridor, turning 180 degrees at the end of 163 every 30m. Standardised instructions and verbal encouragement were given.

164 Secondary outcomes

165 **Isometric muscle strength**

A hand held dynamometer (MicroFET2 Torque/Force indicator, Hoggan
 Health Industries, Utah, US) validated for assessing functional leg strength in elderly
 populations was used.²¹ Participants sat in an elevated chair and were instructed to

169 maximally extend the knee while the assessor provided an equal and opposite

resistive force, against the lower shin. Mean force generated was measured in
 Newtons.

172 Quality of Life: Minnesota Living with Heart Failure Questionnaire (MLHFQ)

The MLWHF questionnaire is a disease validated questionnaire,²² that has been extensively used in heart failure studies. Questionnaire scores range from 0 to 105, with higher scores reflecting lower Quality of life. Participants were asked to answer each question based on their perception of health in the week previous to testing.

178 **Physical Activity levels**

Physical activity levels were measured by the Bodymedia© SenseWear Pro3 Armband. The multi-plane accelerometer was worn continuously for the seven days prior to testing to determine Total Energy Expenditure (TEE) per 24hr period was used as the main indicator of physical activity.

183 **LF-EMS acceptability questionnaire**

At the end of the trial participants were given a brief questionnaire used in previous
 LF-EMS studies,^{13,14} to collect feedback on the acceptability of using LF-EMS
 regularly. Questions used the likert scale and covered ease of use, comfort,
 tolerability and overall satisfaction.

188 Safety: Blood test

Venous blood samples were taken at baseline, four weeks and eight weeks to
 assess creatine kinase (CK), urea, and electrolytes. Participants would discontinue
 the trial if levels exceeded the upper limit of normal reference ranges

192 Data analysis

Data analyses for the feasibility objectives of this study were descriptive, based on the pre-determined levels specified above. Confidence intervals (set at 95%) were calculated for all secondary outcome measures in both groups and paired two-sample t-test conducted for between group comparisons. Intent-to-treat (ITT) analysis was employed in this study as is recommended for clinical trials.²⁴

198

200 Results

201 Feasibility criteria outcomes

202 Recruitment

203 There were 171 eligible participants identified in the Coventry and

204 Warwickshire area from November 2013 - April 2015. Sixty of 171 eligible

205 participants (35.08%) were recruited to the trial. Participants were randomised and

started on the trial during this period and were followed up until data collection

finished in August 2015. Participant characteristics are presented in Table 1.

209	Table 1. Baseline demographic and clinical characteristics of the LF-EMS and sham
210	placebo groups. Data presented as mean \pm SD or absolute number and percent.

Demographics	LF-EMS (n-30)	Sham (n=30)
n Male	20 (66%)	22 (73%)
Age (yrs)	66.5 ± 7.8	66.8 ± 13.5
Body Mass Index (kg/m ²)	30.1 ± 4.9	27.8 ± 4.8
Comorbidities		
Prev MI/PCI/CABG	17 (56%)	11 (36%)
Diabetes	12 (40%)	10 (33%)
COPD	9 (30%)	8 (26%)
AF	20 (66%)	16 (53%)
Hypertension	13 (43%)	10 (33%
CKD	5 (16%)	13 (43%)
Clinical		
NT-pro-BNP (pg/mL)	3086 ± 3746	2046 ± 2545
Creatinine (µmol/L)	108 ± 49	113 ± 39
LVEF %	39 ± 11*	$22\pm12^{**}$
BP _{sys} (mmHg)	118 ± 16	126 ± 17
BP _{dia} (mmHg)	69 ± 9	74 ± 14
NYHA III	24 (80%)	22 (73%)
NYHA IV	6 (20%)	8 (26%)

NT-pro-BNP (pg/mL),N-terminal pro B-type natriuretic peptide; LVEF; left ventricular
ejection fraction; BP_{sys} (mmHg), systolic blood pressure; BP_{dia} (mmHg), diastolic
blood pressure; NYHA, New York Heart association; MI, myocardial infarction; PCI,
percutaneous coronary intervention; CABG, coronary artery bypass graft surgery;
COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; CKD, chronic
kidney disease;

*n=10.Ejection fraction could not be accurately assessed in all patients due to poor
 body habitus/atrial fibrillation. An experienced cardiac sonographer made an 'eyeball'
 assessment of poor left ventricular function for all other participants


240 **n=5. See previous comments.

241

242

244 Retention

Twelve of the 60 participants (4 LF-EMS, 8 sham) (20%) withdrew and did not 245 finish the intervention period (See Fig 1). Of these, only three found the intervention 246 247 intolerable (1 LF-EMS, 2 sham). Other reasons for dropout were: deterioration in health (n= 6) family problems (n=2) and implantation of a cardioverter defibrillator 248 249 (ICD) (n=1). Only 22 (45%) of those completing the intervention period returned for 250 follow-up testing at 20 weeks. Reasons for non-follow-up were: deterioration in health (n=9), excluded due to implantation of cardiac resynchronisation therapy 251 252 device (n=2), declined to take part without further explanation (n=13), and could not 253 be contacted after repeated attempts (n=3).



- Figure 1. Flow diagram of a single centre blinded parallel group randomised
- feasibility trial of electrical muscle stimulation versus sham placebo in severe heart failure patients.

278

279

280

282 Adherence

Forty one (85.4 %) of the 48 participants (22-LF-EMS, 19-SHAM) who completed the intervention period (68.3% of the total sample) adhered to the strict protocol for the majority (>70%) of the eight weeks. Interrogation of the LF-EMS controllers revealed that participants in the LF-EMS group became more tolerant to the intervention; mean stimulation intensity increased from 57.79mA (95%CI: 51.16 to 64.42) during week 1 of the study to 84.86mA (95%CI: 75.44 to 94.28) by week 8, an improvement of 46.5%.

290 'Sham' Placebo

The sham placebo for the study appeared to be convincing as only 61% of participants guessed their treatment group correctly. The 95% confidence interval for the proportion of participants guessing correctly was (46% to 74%) and thus not significantly different from 50% which would be expected by chance. Furthermore, participants demonstrated an inclination to guess that they were randomised to LF-EMS regardless of group allocation.

297 Safety

No abnormalities were detected in CK, urea or electrolytes taken before, during or after the study. Likewise, no adverse events due to the intervention were recorded in either group.

301 Primary outcome- 6-minute walk test

302 Non-significant improvements after LF-EMS (8 week time point) and sham groups

were observed in 6 MWD with a mean increase from baseline of 24m (P=0.13)in the

304 LF-EMS group (Table 2.)

305 Secondary outcomes

Table 2 shows the mean values of the secondary outcome measures at each time point. There were no significant differences between groups in the change from baseline for any of the secondary outcome variables (Table 3). There was a nonsignificant improvement in quality of life in both groups.

310

311

Outcome	Time point	LF-EMS	Sham
Mean 6	Baseline <i>(n)</i>	283 [237 – 328] 29	290 [243 – 337] 29
MWD (metres) [95% CI]	8 weeks <i>(n)</i>	312 [262 – 362] 26	318 [270 – 365] 22
	20 weeks <i>(n)</i>	257 [173 – 342] 12	226 [126 – 325] 10
(Mean leg	Baseline <i>(n)</i>	234.3 [196.5 – 272.] 29	297.5 [253 – 342] 29
strength (newtons) [95% CI]	8 weeks <i>(n)</i>	224.9 [187.5 – 262.3] 25	321 [267.8 – 374.3] 22
	20 weeks <i>(n)</i>	181.6 [131.7 – 231.5] 11	207.1 [148.6 – 265.7] 10
Mean	Baseline <i>(n)</i>	53.1 [42.7 – 63.5] 28	50 [40 – 60.1] 29
QoL (score) [95% CI]	8 weeks <i>(n)</i>	43.9 [34.2 – 53.5] 25	43.1 [30.9 – 55.3] 22
	20 weeks <i>(n)</i>	51.7 [31.6 – 71.8] 12	37.0 [16.9 – 57] 10
Mean	Baseline <i>(n)</i>	63,438 [56,170 – 70,705] 25	65,371 [59675 – 71,067] 27
(joules) [95% Cl]	8 weeks <i>(n)</i>	59,783 [51,094 – 68,471] 19	59,687 [50,630 – 68,745] 17
	20 weeks <i>(n)</i>	61,878 [53,345 – 70,410] 7	63,541 [55,795 – 71,287] 6

313	Table 2: Outcome measurements – Time point averages and 95% confidence
314	intervals (CI)

6 MWD, 6 minute walk distance, QoL, quality of life; TEE, Total Energy Expenditure

	_	_	-	-
Outcome	Time point	LF-EMS	Sham	p-value
Maria	Baseline to 8 weeks	24 [9 – 40]	9 [-4 – 22]	0.1366
Mean 6 MWD	(n)	26	22	
(metres) [95% CI]	Baseline to 20 weeks	0 [-32 – 31]	-26.30 [-63 – 11]	0.2409
	(n)	12	10	
	Baseline to 8 weeks	-9.2 [-28.9 – 10.5]	6.0 [-19.3 – 31.4]	0.3244
(Mean leg strength	(n)	25	22	
(newtons) [95% CI]	Baseline to 20 weeks	-43.4 [-78.7 – -8.2]	-74.1 [-116.3 – - 31.9]	0.2223
	(n)	11	10	
	Baseline to 8 weeks	-7.6 [-15.5 – 0.3]	-4.7 [-10.5 – 1.0]	0.5505
Mean QoL (score)	(n)	25	22	
[95% CI]	Baseline to 20 weeks	1.5 [-12.5 – 15.7]	-14.0 [-34 – 6]	0.1610
	(n)	12	10	
	Baseline to 8 weeks	-4635 [-3963 – 4692]	-8168 [-14,342 – - 1995]	0.5108
Mean TEE (joules)	(n)	19	17	
[95% CI]	Baseline to 20 weeks	1686 [-6435 – 9809]	4177 [-7695 — 16,050]	0.6634
	(n)	7	6	

317	Table 3: -Changes from	baseline averages and 9	95% confidence intervals (CI)
	5	5	

318 6 MWD, 6 minute walk distance; QoL, quality of life; TEE, Total Energy Expenditure

322 Acceptability questionairre

323 Participants responses to the LF-EMS acceptability questionairre

324 are summarised in table 4. The mean response to putting on the straps was 2 ('quite

easy') and the overall mean satisfaction of participants with the intervention was 6

out of 10. Mean responses to comfort, sensation, tolerability and continued use of LF-

EMS were between 3 (medium) and 4 (quite hard/unpleasant).

329 Table 4. Mean responses to acceptability questionairre and standard deviations

Ques	Mean		
		response	
1.	I found putting on the straps (1-easy, 5-hard)	2.0	(±1.17)
2.	At the highest intensity I found the comfort level (1- acceptable, 5-unacceptable)	3.5	(±1.19)
3.	Overall I found the sensation (1-pleasant, 5-unpleasant)	3.3	(±1.13)
4.	I found putting on the LF-EMS for an hour (1-easy, 5- hard)	3.1	(±1.08)
5.	I think I would find staying on a LF-EMS training routine (1-easy, 5-hard)	3.4	(±1.29)
6.	Overall satisfaction with LF-EMS as a way of improving your fitness (1-none,10 extremely satisfied)	6.0	(±1.94)

330

331 Sample size calculation

332

333 The point estimate from the study and the upper CI limit of this estimate were 334 calculated. The upper CI limit was used for the sample size calculation. For detecting the observed difference of 13.4 metres in this study a sample size of 240 335 patients per group would be required. However, a recent study ²⁵ suggested that the 336 minimal clinically important difference for 6MWD is 36 metres in mild-moderate CHF 337 patients. The clinical benefit of the effect size in this study should be considered 338 339 before proceeding with a larger trial 340 341

342 **Discussion**

The predetermined criteria for proceeding to a larger trial were achieved for dropout (20%), adherence (68.3%) and sham placebo efficacy (61.53% participants guessed correctly). However, only 35.06% of eligible patients were recruited, below the target of 40%. Initial outcome measures revealed no significant difference between intervention and placebo groups, although there was a non-significant improvement in 6MWD and guality of life after LF-EMS.

349

350 Feasibility outcomes

351 Recruitment

Percentage uptake (35.06%) of eligible patients in the study was below the predetermined criteria of 40%. This is similar to the poor uptake of conventional cardiac rehabilitation (CR) nationally in the UK: less than 40% of eligible heart failure patients accessed CR in the most recent National Audit of Cardiac Rehabilitation.²⁶

356 Retention/adherence/tolerance

357 One strength of this study is the good level of adherence (68.3%) and retention (80%) compared with other clinical studies; In the HF-ACTION trial,²⁷ only 358 359 40% of patients in the exercise group (n=1159) reported adherence to recommended 360 training volumes after three months. This may have been because of the ease of independent use at home of LF-EMS, in combination with the weekly supervised 361 362 sessions with an exercise physiologist. The patients recruited in the present trial 363 were more debilitated yet they engaged more with LF-EMS than those in the HF-ACTION trial, ²⁷ suggesting that LF-EMS maybe more acceptable to this population 364 365 than conventional exercise.

The dropout at 3 months follow-up was lower than expected due to ill health, device implantation and apathy, and would be challenging to overcome in a larger trial. Strategies to combat dropout could include combining assessment with clinical patient appointments to ensure compliance or arranging home visits for some assessments.

Feedback from the acceptability questionnaires may also be useful in curtailing dropout in a larger trial: the LF-EMS group generally thought that wearing the straps for an hour was 'medium' to 'quite hard/unpleasant'. Continued use of a LF-EMS was deemed challenging also so it is possible that a reduced frequency of LF-EMS whilst still maintaining a sufficient dose e.g. 3 x 1 hr a week may enhance long term adherence.

Tolerance to the LF-EMS intervention improved during the study. Mean current intensity increased by 46% from week one to week eight. This tolerance effect is in keeping with an earlier study by Crognale, et al,¹³ that showed a 20% increase in healthy active adults. The active adults tolerated higher absolute stimulation levels than in this study, both before and after habituation, suggesting that advanced CHF patients are subjectively less tolerant to LF-EMS than a healthy population. In addition, the user feedback collected seems to support this view.
Vivodtzev and colleagues,²⁸ examined factors determining tolerance of EMS in
pulmonary patients. The study reported that lower tolerance to EMS was associated
with greater severity of condition, fat free mass and inflammatory response. It is
possible that the same is true in the CHF population but more research is needed to
confirm this.

389 Outcome Measures

Baseline 6MWD was higher in our study sample than in other advanced heart failure 390 studies.²⁹ This may have been due to high variability because of a few outliers in 391 each group. This reflects the subjective nature of the NYHA classification system. 392 393 However, signs and symptoms of advanced heart failure were primarily the eligibility criteria for this study and not 6MWD. In addition, the ≤300-m distance cutoff (below 394 395 which our baseline mean falls) is often cited, as prognostically important and 396 reflective of advanced disease in many investigations.^{30,31,32} The non-significant improvements in exercise capacity as measured by 6 minute walk were smaller than 397 398 those in a meta-analysis of EMS in heart failure patients by Smart, Dieberg and 399 Gialluria.¹⁰ These authors reported a combined improvement in 6MWD of 46.9m vs 400 usual care or placebo, compared to the effect size of 13.2m in this study. However, 401 patients in this study were more symptomatic than those included in the metaanalysis,¹⁰ and thus had a lower baseline exercise capacity (286m vs 342m.) 402 Nevertheless the mean relative increase (5%) in walk distance of participants in the 403 LF-EMS group is within the measurement error associated with this test.³³ and 404 probably should not be considered clinically significant.²⁵ The extrapolation from 405 406 these results that severe CHF patients are beyond help from EMS maybe premature; a longer training period maybe required to show meaningful changes in exercise 407 408 capacity, particularly as some participants took longer to tolerate meaningful EMS 409 intensities than others.

410

411 Quality of life (MLHFQ) improved in both groups after the intervention. This may, in

412 part, relate to the psychosocial benefits of engaging with researchers regularly in the 413 cardiac rehabilitation facility.³⁴ The placebo effect of both interventions and its

414 influence on patients' perception of well-being should not be underestimated.

Based on previous research by Banerjee et al,^{15,16} and numerous high 415 frequency EMS studies, 35, 36, 12 improvement in leg strength after use of LF-EMS was 416 417 expected. The current trial however, showed no significant change in muscle strength. Muscle wasting, prevalent in many advanced heart failure patients,³⁷ could 418 419 explain this observation. The chronic impairment of muscle tissue caused by heart failure affects the muscle and skin nerve receptors and hence contractility of the 420 421 weakened muscle.³⁸ Participants with more functional leg muscles therefore, may have received greater stimulus to muscle tissue that others did for the same level of 422 423 current intensity. This suggests that LF-EMS may not be effective for all advanced 424 CHF patients.

425 Limitations

The sample for this study was small as is recommended for feasability
studies¹⁹ and this limits the external validity of our findings. Participants were
deemed eligible for the study based on the judgment of experienced heart failure

- 429 clinicians using available knowledge. This may have led to greater variability in
- 430 disease severity/limitation than was intended. The current amplitude (mA) stimulus
- 431 intensity that participants chose to use was a limitation to the study design.
- 432 Participants were instructed to adhere to the 'maximum tolerable intensity' during LF-
- 433 EMS sessions. Due to considerable individual differences in the subjective
- 434 perception of discomfort associated with EMS, It is therefore likely that there was
- 435 variability in the intensity that individuals received

436 **Conclusion**

437 As some of the predetermined feasibility criteria were met in this trial, a larger 438 study into the effects of LF-EMS on advanced heart failure patients could be 439 undertaken. However this 'difficult to engage with' patient group would be very 440 challenging to recruit and follow-up in sufficient numbers to provide definitive data on 441 its efficacy. The improvements seen in this study in 6MWD, and quality of life 442 measures, were not statistically significant. Leg strength and physical activity levels 443 showed no significant change. A longer intervention period than 8 weeks could be 444 considered, to give participants more time to adjust to the intervention. More 445 investigation is required to determine which CHF patients are unresponsive to LF-446 EMS due to severe muscle dysfunction.

A larger trial may be feasible with this difficult population: however, it is
unlikely that the non-significant improvement in exercise capacity and quality of life
found in this pilot study justifies a larger pragmatic trial.

450 Acknowledgements

451 We would like to thank Matthew Annals for his recruitment expertise and for 452 administering the intervention to participants. We would also like to thank Josie 453 Goodby for her assistance and patience during all assessments.

454 Author affiliations

- 455 1(Department of Cardiac Rehabilitation) University Hospitals Coventry &
- 456 Warwickshire NHS Trust, UK
- 457 2University of Warwick (Clinical Trials Unit), UK
- 458 3 Liverpool John Moores University, UK
- 459 4 Cardiff Metropolitan University, UK
- 460 5 University Hospitals of Leicester NHS trust, UK
- 461 6 University of Coventry, UK

462 Author contributions

- 463 SE, GM and PB contributed to the conception of the work. SE, GM, PB, SS, HJ, RS,
- and TH contributed to the design of the work. SE and GM contributed to the
- acquisition, of the work. SE, GM, PB, SS, HJ, RS, and TH contributed to the,
- analysis, or interpretation of data for the work. SE and GM drafted the manuscript.
- 467 PB, SS, HJ, RS, and TH critically revised the manuscript. All gave final approval and
- agree to be accountable for all aspects of work ensuring integrity and accuracy

469Funding

- 470 This study was funded by a National Institute for Health Research (NIHR) Research
- 471 for Patient Benefit (RfPB) award.

472 **Declaration of Conflicting Interests**

- 473 The Author(s) declare(s) that there is no conflict of interest
- 474 Ethics approval NRES Committee West Midlands Coventry &
- 475 Warwickshire13/WM/0240

476 Disclaimer

This article/paper/report presents independent research funded by the
National Institute for Health Research (NIHR). The views expressed are those of the
author(s) and not necessarily those of the NHS, the NIHR or the Department of
Health.

481 **Data sharing statement**

- 482 All available data can be obtained by contacting the corresponding author:
- 483 stuart.ennis@uhcw.nhs.uk

484 **References**

- 485 1. Ambrosy, AP, Fonarow, GC, Butler J et al. The global health and economic
- 486 burden of hospitilizations for heart failure: lessons learned from HHF registries.
- 487 J Am Coll Cardiol. 2014; 63:1123-33
- 488 2. NICE 2010 guideline:CG108 Chronic heart failure (2010). available at:
- 489 http://guidance.nice.org.uk/CG108NICEGuidance/pdf/English (accessed January490 2016)
- 491 3. Kop WJ, Synowski SJ, Gottlieb SS. Depression in heart failure: biobehavioral
 492 mechanisms. *Heart Fail Clin*. 2011;7(1): 23-38.
- 493 4. Taylor RS, Sagar VA, Davies EJ et al. Exercise-based rehabilitation for heart
- 494 failure. *Cochrane Database Syst Rev.* 2014;(4):CD003331. doi:
- 495 10.1002/14651858.CD003331.pub4
- 496 5. Piepoli M, Conraads V, Corrà U et al. Exercise training in heart failure: from theory
 497 to practice. A consensus document of the Heart Failure Association and the

498 European Association for Cardiovascular Prevention and Rehabilitation. *Eur J*499 *Heart Fail.* 2011;13:347–357

500 6. Höllriegel R, Winzer EB, Linke A et al. Long-Term Exercise Training in Patients

501 With Advanced Chronic Heart Failure: SUSTAINED BENEFITS ON LEFT

502 VENTRICULAR PERFORMANCE AND EXERCISE CAPACITY J Cardiopulm

- 503 Rehabil Prev. 2016;36(2):117-24
- 7. Piepoli MF, Davos C et al. ExTraMATCH Collaborative Exercise training metaanalysis of trials in patients with chronic heart failure (ExTraMATCH). *BMJ*.
 2004;1(24): 328(7433):189
- 507 8. Sullach JA, Goldstein S. Use of beta-blockers in chronic heart failure. *Ann Med.*508 2003; 35: 259-66.
- 509 9. Flather MD, Yusuf S, Køber L,et al. Long term ACE inhibitor therapy in patients
 510 with heart failure or left ventricular dysfunction: a systemic overview of the data
 511 from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group
 512 Lancet. 2000;355:1578-81.
- 513 10. Smart NA, Dieberg G and Giallauria F. Functional electrical stimulation for
 514 chronic heart failure: a meta-analysis. *Int J Cardiol.* 2013;167(1): 80-86.
- 515 11. Nuhr, MJ, Pette D, Berger R et al. Beneficial effects of chronic low-frequency
 516 stimulation of thigh muscles in patients with advanced chronic heart failure. *Eur*517 *Heart J.* 2004;25(2): 136-143.
- 518 12. Dobsak P, Novakova M, Siegelova J et al. Low-frequency electrical stimulation
 519 increases muscle strength and improves blood supply in patients with chronic
 520 heart failure. *Circ J.* 2006;70(1): 75-82.
- 521 13. Crognale D, Vito GD, Grosset JF et al. (2013). Neuromuscular electrical
 522 stimulation can elicit aerobic exercise response without undue discomfort in
 523 healthy physically active adults. *J Strength Cond Res.* 2013; 27(1): 208-215.

Minogue CM, Caulfield BM, Lowery MM. Whole body oxygen uptake and evoked
torque during sub-tetanic isometric electrical stimulation of the quadriceps
muscles in a single 30-minute session. *Arch Phys Med Rehabil.* 2014;
95(9):1750-8.

528 15. Banerjee P, Clark A, Witte K et al. Electrical stimulation of unloaded muscles
529 causes cardiovascular exercise by increasing oxygen demand. *Eur J Cardiovasc*530 *Prev Rehabil.* 2005;12(5): 503-508.

16. Banerjee P, Caulfield B, Crowe L et al. Prolonged electrical muscle stimulation
exercise improves strength, peak VO₂, and exercise capacity in patients with
stable chronic heart failure. *J Card Fail.* 2009;15(4): 319-326.

17. Nieminen MS, Dickstein K, Fonseca C et al. The patient perspective: Quality of
life in advanced heart failure with frequent hospitalisations. *Int J Cardiol.* 2015;
191:256-64.

- 18. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies:
 recommendations for good practice. *J Eval Clin Pract.* 2004;10(2):307-12.
- 539 19. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: The what, why and
 540 How. *BMC Medical Research Methodology.* 2010; (2)10:1.
- 541 20. Holland AE, Spruit MA, Troosters T et al. An official European Respiratory
 542 Society/American Thoracic Society technical standard: field walking tests in
 543 chronic respiratory disease. *Eur Respir J.* 2014;44(6): 1428-46.
- 544 21. Schaubert KL and Bohannon RW. Reliability and validity of three strength
 545 measures obtained from community-dwelling elderly persons *J Strength Cond*546 *Res.* 2005;19(3): 717-720
- 547 22. Rector TS and Cohn JN. Assessment of patient outcome with the Minnesota
 548 Living with Heart Failure questionnaire: reliability and validity during a
 549 randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan
 550 Multicenter Research Group. *Am Heart J.* 1992;124(4): 1017-1025.

- 551 23. Krueger, C. and Tian L. A comparison of the general linear mixed model and
 552 repeated measures ANOVA using a dataset with multiple missing data points.
- 553 Biol Res Nurs. 2004;6(2): 151-157.
- 24. Alshurafa M, Briel M, Akl EA et al. Inconsistent definitions for intention-to-treat in
 relation to missing outcome data: systematic review of the methods literature. *PLoS One.* 2012; 7(11): e49163.
- 557 25. Täger T, Hanholz W, Cebola R, et al. Minimal important difference for 6-minute
 558 walk test distances among patients with chronic heart failure. *Int J Cardiol.*559 2014;176(1):94-8.
- 560 26. The National Audit of Cardiac Rehabilitation—Annual Statistical Report 2015-
- 561 2016. Available from <u>http://www.cardiacrehabilitation.org.uk/docs/2007.pdf</u>,

562 27. O'Connor CM, Whellan DJ, Lee KL et al. Efficacy and safety of exercise training
563 in patients with chronic heart failure: HF-ACTION randomized controlled trial.
564 JAMA. 2009; 301(14): 1439-1450.

- 28. Vivodtzev I, Rivard B, Gagnon P et al. Tolerance and physiological correlates of
 neuromuscular electrical stimulation in COPD: a pilot study. *PLoS One.* 2014;
 9;9(5):e94850. doi: 10.1371/journal.pone.0094850
- 29. Reeves GR, Whellan DJ, O'Connor CM et al. A Novel Rehabilitation
 Intervention for Older Patients With Acute Decompensated Heart Failure *JACC: Heart Failure* 2017, 613; DOI: 10.1016/j.jchf.2016.12.019
- 30. Guazzi M, Dickstein K, Vicenzi R and Arena R. Six-Minute Walk Test and
 Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure.
- 573 *Circulation: Heart Failure*. 2009; 2:549-555.
- 31. Arslan S, Erol MK, Gundogdu F et al. Prognostic value of 6-minute walk test in
 stable outpatients with heart failure. *Tex Heart Inst J.* 2007; **34**: 166–169.

- 32. Rostagno C, Olivo G, Comeglio M, et al. Prognostic value of 6-minute walk
 corridor test in patients with mild to moderate heart failure: comparison with other
 methods of functional evaluation.2003 *Eur J Heart Fail.* 5: 247–252.
- 33. Zugck C, Krüger C, Dürr S et al. Is the 6-minute walk test a reliable substitute for
 peak oxygen uptake in patients with dilated cardiomyopathy? *Eur Heart J*. 2000;
 21(7):540-9
- 34. Jeon YH, Kraus SG, et al. The experience of living with chronic heart failure: a
 narrative review of qualitative studies. *BMC Health Serv Res.* 2010 24;10:77
- 35. Quittan M, Wiesinger GF, Sturm B et al. Improvement of thigh muscles by
 neuromuscular electrical stimulation in patients with refractory heart failure: a
 single-blind, randomized, controlled trial *Am J Phys Med Rehabil.* 2001;80(3):
 206-214
- 36. Harris S, LeMaitre JP, Mackenzie G et al. A randomised study of home-based
 electrical stimulation of the legs and conventional bicycle exercise training for
 patients with chronic heart failure. *Eur Heart J.* 2003;24(9): 871-878.
- 591 37. Fülster S, Tacke M, Sandek A et al. Muscle wasting in patients with chronic heart
 592 failure: results from the studies investigating co-morbidities aggravating heart
 593 failure (SICA-HF). *Eur Heart J.* 2013;34(7): 512-9.
- 38. Rullman E, Andersson DC, Melin M et al. Modifications of skeletal muscle
 ryanodine receptor type 1 and exercise intolerance in heart failure. *J Heart Lung Transplant*. 2013;32(9):925-9. doi: 10.1016/j.healun.2013.06.026